SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Traders are focused on the upcoming FDA decision on Capricors deramiocel for Duchenne muscular dystrophy, with the November 22 target date, additional upper-limb data, and recent commercial-launch job postings fueling speculation about approval. Bulls view the FDAs rare-disease flexibility and hiring as encouraging, while skeptics stress that approval is uncertain given the programs prior FDA setbacks; claims of a news leak or short covering remain unconfirmed.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has put pressure on Precigens first-mover position with PAPZIMEOS. Traders debate whether the new rival threatens PGENs market share or whether PAPZIMEOS commercial head start and full approval give it an advantage over Inovios accelerated approval.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

Semiconductor shares are under heavy pressure as investors question whether massive AI infrastructure spending will generate sustainable returns, with weak Intel and Amazon results adding to the broader tech selloff. Traders are split between viewing the decline as a deeper unwind of an overheated AI trade and seeing oversold conditions and ongoing chip demand as a buying opportunity.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter earnings, supported by Dupixent collaboration revenue and Eylea HD demand, are driving a sharp share rally. Traders largely describe the results as a breakout and a sign of strong execution, while some are watching the upcoming cemdisiran regulatory decision as another potential catalyst.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has rallied to fresh 52-week highs ahead of an expected Q3 report, with traders focused on BRIUMVI sales momentum and debating whether the move also reflects unconfirmed buyout speculation. Some point to heavy short interest as potential fuel, while others caution that the stock may be priced for strong results.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Robloxs quarterly report beat estimates, but weaker user engagement and a forecast decline in fourth-quarter bookings sparked a sharp selloff. Traders largely voiced bearish concerns about slowing growth and monetization, while some viewed the drop as an overreaction or a buying opportunity.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicares DefenCath reimbursement could decline sharply through 2027 has fueled concerns about pricing and revenue for CorMedixs flagship product. Traders are split: some see the comments as a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMS estimates and potential volume growth as reasons not to overreact.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solars quarterly report and weaker 2026 outlook are driving discussion, with traders weighing a revenue decline against an EPS beat, strong margins and a newly authorized share repurchase. Reactions are split: some see the selloff as excessive given the companys backlog and profitability, while others focus on near-term guidance, policy and subsidy exposure, and broader pressure on solar stocks.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas earnings beat and raised outlook, alongside optimism about identity security for AI agents, fueled a sharp rally. Traders are split on whether that growth opportunity justifies the valuation, with some bullish on the cybersecurity theme and others warning of profit-taking and a correction.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

Semiconductor stocks are under heavy selling pressure after Intels weak outlook and softer PC demand, alongside broader concern that AI investment may not deliver returns quickly enough and reports of fund deleveraging. Traders are split between calling the drop a buying opportunity and warning that the AI trade could face a deeper correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

About CMSSU